No Data
No Data
Estimating The Intrinsic Value Of Belite Bio, Inc (NASDAQ:BLTE)
H.C. Wainwright Maintains Belite Bio(BLTE.US) With Buy Rating, Maintains Target Price $59
H.C. Wainwright analyst Yi Chen maintains $Belite Bio(BLTE.US)$ with a buy rating, and maintains the target price at $59.According to TipRanks data, the analyst has a success rate of 27.2% and a total
Express News | Belite Bio Announces That Its Lead Pipeline, Tinlarebant, Has Been Granted Sakigake Designation By The Ministry Of Health, Labour And Welfare In Japan For The Treatment Of STGD1
Express News | Belite: Lead Pipeline, Tinlarebant, Been Granted Sakigake Designation by Ministry of Health, Labour & Welfare in Japan (Mhlw) for Treatment of Stgd1.
Express News | Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan
Form 144 | Belite Bio(BLTE.US) Insider Proposes to Sell 1.46 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 4, $Belite Bio(BLTE.US)$ Insider Nathan Mata intends to sell 30,000 shares of its common stock on Jun 4, with a total market value of approximately $1.46 million. Nathan
No Data